CN110582495B - 作为tnf活性的调节剂的稠合五环咪唑衍生物 - Google Patents

作为tnf活性的调节剂的稠合五环咪唑衍生物 Download PDF

Info

Publication number
CN110582495B
CN110582495B CN201880025894.6A CN201880025894A CN110582495B CN 110582495 B CN110582495 B CN 110582495B CN 201880025894 A CN201880025894 A CN 201880025894A CN 110582495 B CN110582495 B CN 110582495B
Authority
CN
China
Prior art keywords
methyl
compound
difluoromethoxy
disorders
cis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880025894.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN110582495A (zh
Inventor
D·C·布鲁金斯
T·得哈罗加西亚
Y·福里谢
H·T·霍斯利
M·C·哈钦斯
J·A·约翰逊
M·马考思
宣梦阳
朱昭宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Sanofi SA
Original Assignee
UCB Biopharma SRL
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58632834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110582495(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB Biopharma SRL, Sanofi SA filed Critical UCB Biopharma SRL
Publication of CN110582495A publication Critical patent/CN110582495A/zh
Application granted granted Critical
Publication of CN110582495B publication Critical patent/CN110582495B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880025894.6A 2017-04-25 2018-04-24 作为tnf活性的调节剂的稠合五环咪唑衍生物 Active CN110582495B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17168027 2017-04-25
EP17168027.5 2017-04-25
PCT/EP2018/060489 WO2018197503A1 (en) 2017-04-25 2018-04-24 Fused pentacyclic imidazole derivatives as modulators of tnf activity

Publications (2)

Publication Number Publication Date
CN110582495A CN110582495A (zh) 2019-12-17
CN110582495B true CN110582495B (zh) 2022-04-01

Family

ID=58632834

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880025894.6A Active CN110582495B (zh) 2017-04-25 2018-04-24 作为tnf活性的调节剂的稠合五环咪唑衍生物

Country Status (33)

Country Link
US (4) US10980814B2 (https=)
EP (2) EP3615534B1 (https=)
JP (2) JP7083358B2 (https=)
KR (1) KR102565132B1 (https=)
CN (1) CN110582495B (https=)
AR (1) AR111426A1 (https=)
AU (1) AU2018259040B2 (https=)
CA (1) CA3058980A1 (https=)
CL (1) CL2019002875A1 (https=)
CO (1) CO2019012856A2 (https=)
CR (1) CR20190526A (https=)
DK (1) DK3615534T3 (https=)
EA (1) EA039049B1 (https=)
ES (2) ES2893807T3 (https=)
HR (1) HRP20211927T1 (https=)
HU (1) HUE056593T2 (https=)
IL (1) IL269890B (https=)
LT (1) LT3615534T (https=)
MA (2) MA49055B1 (https=)
MX (1) MX2019012443A (https=)
MY (1) MY197212A (https=)
PE (1) PE20200662A1 (https=)
PH (1) PH12019502182B1 (https=)
PL (2) PL3939980T3 (https=)
PT (2) PT3939980T (https=)
PY (1) PY1829804A (https=)
RS (1) RS62596B1 (https=)
SG (1) SG11201908871SA (https=)
SI (1) SI3615534T1 (https=)
TW (1) TWI801378B (https=)
UY (1) UY37700A (https=)
WO (1) WO2018197503A1 (https=)
ZA (1) ZA201906255B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10766906B2 (en) * 2016-04-01 2020-09-08 UCB Biopharma SRL Fused hexacyclic imidazole derivatives as modulators of TNF activity
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CA3117344A1 (en) * 2018-10-24 2020-04-30 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of tnf activity
CN120418259A (zh) 2022-11-23 2025-08-01 弗沃德医疗公司 TNFα活性的调节剂
TW202508596A (zh) 2023-04-26 2025-03-01 法商賽諾菲公司 使用腫瘤壞死因子α之小分子抑制劑治療乾癬
WO2024251282A1 (zh) * 2023-06-09 2024-12-12 上海翰森生物医药科技有限公司 五环类衍生物抑制剂、其制备方法和应用
TW202519231A (zh) 2023-07-04 2025-05-16 法商賽諾菲公司 結晶形式
TW202521544A (zh) 2023-08-16 2025-06-01 美商雷瑟拉股份有限公司 TNFα活性調節劑及其用途
WO2025068505A1 (en) 2023-09-29 2025-04-03 Sanofi Preparation of bridged pentacyclic imidazole derivatives as modulators of tnf activity, intermeditates and their preparation
TW202602881A (zh) * 2024-03-27 2026-01-16 大陸商海思科醫藥集團股份有限公司 雜環衍生物及其在醫藥上的應用
WO2025212627A1 (en) 2024-04-03 2025-10-09 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
WO2025218735A1 (zh) * 2024-04-17 2025-10-23 上海翰森生物医药科技有限公司 五环类衍生物抑制剂、其制备方法和应用
WO2025247401A1 (zh) * 2024-05-31 2025-12-04 海思科医药集团股份有限公司 一种稠合杂环衍生物及其在医药上的应用
WO2025252251A1 (zh) * 2024-06-07 2025-12-11 上海翰森生物医药科技有限公司 含氧杂环类衍生物抑制剂、其制备方法和应用
WO2026012303A1 (en) * 2024-07-09 2026-01-15 Hangzhou Highlightll Pharmaceutical Co., Ltd NOVEL BENZO [4, 5] IMIDAZO COMPOUNDS AS TNFα MODULATORS
WO2026022134A1 (en) 2024-07-23 2026-01-29 Sanofi Novel aminocarbonylation processes
WO2026021586A1 (zh) * 2024-07-26 2026-01-29 上海瀚辰星泰医药科技有限公司 一种多环化合物及其制备方法和应用
WO2026027449A1 (en) 2024-07-29 2026-02-05 Sanofi Fused pentacyclic imidazole derivatives
WO2026051930A1 (zh) * 2024-09-04 2026-03-12 苏州湃玥生物科技有限公司 一种作为tnf活性调节剂的稠合五环苯并咪唑衍生物及其制备方法和应用
WO2026055519A1 (en) 2024-09-06 2026-03-12 Rapt Therapeutics, Inc. Fused ring imidazole compounds
WO2026064602A1 (en) * 2024-09-23 2026-03-26 Synnovation Therapeutics, Inc. HETEROCYCLIC COMPOUNDS AS MODULATORS OF TNFα ACTIVITY
WO2026068677A1 (en) 2024-09-27 2026-04-02 Sanofi Processes for the preparation of fused pentacyclic imidazoles and intermediates

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104428293A (zh) * 2012-06-11 2015-03-18 Ucb生物制药私人有限公司 调节TNFα的苯并咪唑类
CN104470924A (zh) * 2012-07-13 2015-03-25 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡嗪衍生物
CN104619709A (zh) * 2012-07-13 2015-05-13 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
WO2016050975A1 (en) * 2014-10-03 2016-04-07 Ucb Biopharma Sprl Fused pentacyclic imidazole derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
EP3288939A1 (en) * 2015-04-17 2018-03-07 AbbVie Inc. Tricyclic modulators of tnf signaling

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104428293A (zh) * 2012-06-11 2015-03-18 Ucb生物制药私人有限公司 调节TNFα的苯并咪唑类
CN104470924A (zh) * 2012-07-13 2015-03-25 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡嗪衍生物
CN104619709A (zh) * 2012-07-13 2015-05-13 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
WO2016050975A1 (en) * 2014-10-03 2016-04-07 Ucb Biopharma Sprl Fused pentacyclic imidazole derivatives

Also Published As

Publication number Publication date
HRP20211927T1 (hr) 2022-03-18
US20210252012A1 (en) 2021-08-19
AU2018259040A1 (en) 2019-10-31
DK3615534T3 (da) 2021-10-18
MA49055A (fr) 2021-05-05
MA57699B1 (fr) 2023-11-30
PH12019502182B1 (en) 2024-01-31
CR20190526A (es) 2020-01-07
UY37700A (es) 2018-11-30
JP7299382B2 (ja) 2023-06-27
CL2019002875A1 (es) 2020-03-06
EP3939980B1 (en) 2023-07-26
US20200046723A1 (en) 2020-02-13
KR102565132B1 (ko) 2023-08-08
SI3615534T1 (sl) 2022-01-31
AR111426A1 (es) 2019-07-10
AU2018259040B2 (en) 2022-04-28
EP3615534B1 (en) 2021-09-15
CN110582495A (zh) 2019-12-17
JP2022116233A (ja) 2022-08-09
PL3615534T3 (pl) 2022-01-31
LT3615534T (lt) 2021-11-25
TWI801378B (zh) 2023-05-11
SG11201908871SA (en) 2019-10-30
PY1829804A (es) 2019-03-01
IL269890B (en) 2022-03-01
WO2018197503A1 (en) 2018-11-01
ZA201906255B (en) 2021-01-27
ES2956555T3 (es) 2023-12-22
HUE056593T2 (hu) 2022-02-28
MA49055B1 (fr) 2021-12-31
BR112019020314A2 (pt) 2020-04-28
EA201992407A1 (ru) 2020-04-06
MX2019012443A (es) 2020-01-13
EA039049B1 (ru) 2021-11-26
KR20190141200A (ko) 2019-12-23
US20230250105A1 (en) 2023-08-10
RS62596B1 (sr) 2021-12-31
JP7083358B2 (ja) 2022-06-10
PE20200662A1 (es) 2020-06-11
EP3615534A1 (en) 2020-03-04
ES2893807T3 (es) 2022-02-10
PT3615534T (pt) 2021-10-21
US10980814B2 (en) 2021-04-20
PH12019502182A1 (en) 2020-06-08
JP2020517637A (ja) 2020-06-18
CO2019012856A2 (es) 2020-01-17
EP3939980A1 (en) 2022-01-19
PL3939980T3 (pl) 2024-02-05
TW201841918A (zh) 2018-12-01
US20250127795A1 (en) 2025-04-24
NZ758198A (en) 2024-01-26
PT3939980T (pt) 2023-08-07
CA3058980A1 (en) 2018-11-01
MY197212A (en) 2023-06-01

Similar Documents

Publication Publication Date Title
CN110582495B (zh) 作为tnf活性的调节剂的稠合五环咪唑衍生物
TWI616436B (zh) 作為ｍａｇｌ抑制劑的胺基甲酸１，１，１－三氟－３－羥基丙烷－２－基酯衍生物及胺基甲酸１，１，１－三氟－４－羥基丁烷－２－基酯衍生物
CN107074804B (zh) 咔唑衍生物
CN107820494B (zh) 核受体调节剂
CN113227097A (zh) 作为tnf活性调节剂的稠合五环咪唑衍生物
TW201838981A (zh) 嘧啶基-吡啶氧基-萘基化合物以及治療ire1相關之疾病及病症的方法
CN112004802A (zh) 作为神经元组胺受体-3拮抗剂的化合物及其用途
WO2021208918A1 (zh) 作为egfr抑制剂的三环化合物
CN116600808A (zh) 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用
WO2024217481A1 (zh) Egfr降解剂、其药物组合物及其用途
CN108017633A (zh) N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用
CN115667259A (zh) 抑制h-pgds的稠环化合物
CN109476638A (zh) 吡唑衍生物、其组合物及治疗用途
HK40058586B (en) Process for preparing fused pentacyclic imidazole derivatives and uses thereof as modulators of tnf activity
HK40058586A (en) Process for preparing fused pentacyclic imidazole derivatives and uses thereof as modulators of tnf activity
JP2025536323A (ja) 縮合二環式化合物ならびにＭｅｒ阻害剤およびＡｘｌ阻害剤としてのその使用
HK40129387A (zh) 造血前驱细胞激酶1的吡啶酮及嘧啶酮抑制剂
JP2024543028A (ja) ピルビン酸キナーゼモジュレーターとしてのフタラジン誘導体
BR112019020314B1 (pt) Derivados de imidazol pentacíclico fundido como moduladores da atividade de tnf, composição farmacêutica compreendendo os mesmos e uso dos mesmos
WO2022057849A1 (zh) 哌嗪类衍生物及其制备方法和用途
HK40024466B (en) Fused pentacyclic imidazole derivatives as modulators of tnf activity
HK40024466A (en) Fused pentacyclic imidazole derivatives as modulators of tnf activity
HK40035008B (zh) 杂环基氨基取代的三唑类化合物作为rho相关蛋白激酶的调节剂
TW201910325A (zh) 吲哚衍生物及其用途
HK1248678B (zh) 核受体调节剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant